Eli Lilly Hikes UK Mounjaro Price
Analysis based on 10 articles · First reported Aug 14, 2025 · Last updated Aug 15, 2025
The price hike of Tirzepatide by Eli Lilly and Company in the United Kingdom for private patients is expected to increase revenue for Eli Lilly and Company, potentially leading to lower drug prices in the United States. This move could also benefit competitors like Novo Nordisk as some UK private patients may switch to alternative weight-loss drugs.
Eli Lilly and Company is set to dramatically increase the price of its weight-loss and diabetes drug Tirzepatide in the United Kingdom by up to 170% for private patients, effective September 1. This decision aims to address pricing inconsistencies compared to other developed countries and ensure fairer global contributions to funding medical innovation. The United Kingdom — National Health Service in the United Kingdom will not be affected by these price changes, continuing to receive the medication at existing rates. The move comes amid political pressure from Donald Trump, who has advocated for lower drug prices in the United States by encouraging price increases in other developed markets. Eli Lilly and Company stated that the rebalancing of prices, though difficult, is necessary to support the United States as a leader in biopharmaceutical research and manufacturing.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard